Familial mediterranean fever (FMF) is an inherited autoinflammatory disorder characterized by recurrent episodes of fever and painful inflammation involving the intra-abdominal organs, the lungs and the joints, which is highly prevalent in specific ethnic groups including the Iranians. We report a 12-year-old boy from Iran, with a clinical history of recurrent fever. Based on the suggestive clinical data, mutational analysis revealed the presence of the novel c.1945C>T heterozygous variant in exon 10, which leads to a leucine to phenylalanine change at position 649 of the protein.
F amilial mediterranean fever (FMF) is an inherited autoinflammatory disorder characterized by recurrent episodes of fever and serositis, which is highly prevalent in specific ethnic groups, including the Iranians (1) . In patients affected by FMF, more than 300 mutations in the MEFV gene, in particular in the exon 10, have been described, demonstrating the great interest for the role of the MEFV gene in the pathogenesis of FMF. We report the case of a 12-year-old boy, son of non-consanguineous parents from southwestern Iran with a clinical history of recurrent episodes of fever beginning at the age of three, characterized by episodes of hyperpyrexia (max 41ºC) every 3 to 5 weeks and lasting 3 to 5 days, associated with abdominal pain, nausea, vomiting and general myalgia, without arthritis or skin manifestations. Both parents and the one-year-old sister were healthy with no history of periodic fever or other recurrent clinical manifestations. His weight and height were in the normal range. The laboratory examinations during the attacks showed hemoglobin 13 g/ dL, white blood cell count (WBC) 10,000/ μL with 65. 
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ure 1). The mutation, which is not reported in Infevers (3), ClinVar or 1000 genomes, was inherited from the mother. It lies in the exon 10 of the MEFV gene, which encodes for a domain called B30.2-SPRY, located in the C-terminal region of the pyrin protein; this domain is considered crucial for the modulation of the inflammasome activity, consistent with the fact that at least 90 different mutations identified as diseasecausing are located in that exon (4, 5) . The mutation in position 649 may then alter the function of pyrin, consequently suppressing apoptosis and IL-1β activation. Since FMF is inherited mainly as a recessive disease, there may be a second mutation transmitted by the father that was not identified; as a matter of fact, the absence of any mutation in the second allele has been shown in 20-25% of patients with the clinical picture of FMF and a positive response to colchicine therapy (2) . Other possible pathogenic models include a dominant mutation with incomplete penetrance or the interaction of genetic and environmental causes (6) . The present report expands the spectrum of MEFV gene mutations associated with the clinical phenotype of FMF.
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He showed negative tests for antinuclear antibodies (ANA) and rheumatoid factor, normal IgD levels, as well as negative investigations for infectious etiologies including Toxoplasma, Rubella, CMV, HSV and HIV. An autoinflammatory etiology of the disorder was then suspected and a trial therapy with colchicine 0.03 mg/Kg/day was started, with a good response leading in two months to the disappearance of the attacks. Therapy was discontinued after 12 months, with no relapse of fever episodes during the following two years and normality in all the laboratory tests. 
